Abstract
The development of an effective AIDS vaccine remains one of the highest priorities in HIV research. The live, attenuated varicella-zoster virus (VZV) Oka vaccine, safe and effective for prevention of chickenpox and zoster, also has potential as a recombinant vaccine against other pathogens, including human immunodeficiency virus (HIV). The simian varicella model, utilizing simian varicella virus (SVV), offers an approach to evaluate recombinant varicella vaccine candidates. Recombinant SVV (rSVV) vaccine viruses expressing simian immunodeficiency virus (SIV) env and gag antigens were constructed. The hypothesis tested was that a live, attenuated rSVV-SIV vaccine will induce immune responses against SIV in the rhesus macaques and provide protection against SIV challenge. The results demonstrated that rSVV-SIV vaccination induced low levels of neutralizing antibodies and cellular immune responses to SIV in immunized rhesus macaques and significantly reduced viral loads following intravenous challenge with pathogenic SIVmac251-CX-1.
References
Feb 1, 1992·Virology·W L GrayT M Fletcher
May 1, 1992·The Journal of General Virology·T M Fletcher, W L Gray
Feb 11, 1998·Tissue Antigens·L A KnappD I Watkins
Jan 8, 1999·Journal of Medical Primatology·W L GrayK F Soike
Dec 22, 1999·AIDS Research and Human Retroviruses·S M SmithR I Connor
Aug 10, 2000·Journal of Virology·C G MurphyR C Desrosiers
Jul 29, 2004·AIDS·Stephen M SmithPreston A Marx
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Silvija I StapransMark B Feinberg
Sep 24, 2004·Reviews in Medical Virology·Wayne L Gray
Dec 9, 2004·AIDS Research and Human Retroviruses·Michael A EganJohn K Rose
Dec 23, 2004·Journal of Virology·Philip R JohnsonK Reed Clark
Jul 12, 2005·Vaccine·Robert E JohnstonNancy L Davis
Jul 30, 2005·Journal of Virology·Ming LiDavid C Montefiori
Mar 1, 2006·European Journal of Immunology·Bapi PaharRonald S Veazey
Jun 17, 2006·The Journal of Infectious Diseases·Myron J LevinUNKNOWN Pediatric AIDS Clinical Trials Group 265 Team
Nov 23, 2006·AIDS·Vincent BekkerTaco Kuijpers
Apr 17, 2007·Virology·Yang OuWayne L Gray
Feb 15, 2008·The Journal of General Virology·Toby M WardWayne L Gray
Nov 14, 2008·Journal of Virology·Elena CarneroAdolfo García-Sastre
Nov 28, 2008·Virus Genes·Esther GrinfeldPeter G E Kennedy
Mar 21, 2009·Virology·Bapi PaharRonald S Veazey
Nov 17, 2009·PLoS Pathogens·Ilhem MessaoudiRavi Mahalingam
Nov 26, 2009·Retrovirology·Abdelkrim ManniouiRoger Le Grand
May 6, 2010·The Journal of Infectious Diseases·Moeun SonAnne A Gershon
Citations
Feb 13, 2013·The Journal of Experimental Medicine·Laura E McCoy, Robin A Weiss
Feb 15, 2013·Journal of Virology·Gregory Q Del PreteBrandon F Keele
Jul 12, 2013·Advances in Virology·Wayne L Gray
Mar 25, 2015·Vaccine·Margherita RosatiBarbara K Felber
Aug 17, 2010·PloS One·Douglas H SmithPhillip W Berman
Nov 9, 2018·Journal of Virology·Vicki Traina-DorgeRavi Mahalingam
Sep 12, 2020·Vaccines·Ziyu Wen, Caijun Sun
Aug 28, 2019·Current Immunology Reviews·Pamela A Kozlowski, Anna Aldovini
Apr 30, 2021·Journal of Virology·Isabelle M CastroMauricio A Martins
Aug 15, 2012·Virology Journal·Bapi PaharVicki L Traina-Dorge
Nov 16, 2021·Journal of Medical Primatology·Wayne L GrayVicki Traina-Dorge